Boston Scientific beats, but issues Q2 EPS guidance $0.82–$0.84, reaffirms 2026 EPS outlook $3.34–$3.41

 

Boston Scientific beats Q1 2026 estimates with non-GAAP EPS $0.80, revenue $5.203B, issues Q2 EPS guidance $0.82–$0.84, reaffirms 2026 EPS outlook $3.34–$3.41

• GAAP net income reached $1.34B in Q1 2026, approximately doubling compared with the prior-year period.
• Company expects 2026 sales growth of 7.0–8.5% and EPS of $3.34–$3.41.

https://finviz.com/quote.ashx?t=BSX&p=d